1. Home
  2. NVT vs BIIB Comparison

NVT vs BIIB Comparison

Compare NVT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nVent Electric plc

NVT

nVent Electric plc

HOLD

Current Price

$163.30

Market Cap

28.6B

Sector

Industrials

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$206.28

Market Cap

29.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVT
BIIB
Founded
1903
1978
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.6B
29.9B
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
NVT
BIIB
Price
$163.30
$206.28
Analyst Decision
Strong Buy
Buy
Analyst Count
11
25
Target Price
$131.36
$206.83
AVG Volume (30 Days)
2.1M
1.4M
Earning Date
05-01-2026
04-29-2026
Dividend Yield
0.61%
N/A
EPS Growth
118.78
N/A
EPS
2.18
2.15
Revenue
$3,893,100,000.00
$9,890,600,000.00
Revenue This Year
$19.44
N/A
Revenue Next Year
$12.41
N/A
P/E Ratio
$74.33
$96.11
Revenue Growth
29.51
2.22
52 Week Low
$85.72
$127.00
52 Week High
$184.64
$219.72

Technical Indicators

Market Signals
Indicator
NVT
BIIB
Relative Strength Index (RSI) 52.64 55.10
Support Level $149.36 $184.50
Resistance Level $164.35 $218.03
Average True Range (ATR) 7.35 6.23
MACD 1.60 0.42
Stochastic Oscillator 78.68 55.89

Price Performance

Historical Comparison
NVT
BIIB

About NVT nVent Electric plc

NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: